Physician profile
Rise Mitchell
NPI 1639503816
$4,537.27
in general payments reported to CMS, 2019-2025
25 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $745 · 2023: $1,278 · 2024: $2,026 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Travel and Lodging: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.96 |
| Travel and Lodging | $965.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,348.91 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $689.37 | 2023-2025 | Caplyta |
| Abbvie INC. | $487.34 | 2021-2024 | |
| Axsome Therapeutics, INC. | $281.96 | 2023-2025 | Auvelity |
| Lundbeck LLC | $207.71 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $201.73 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $174.38 | 2021-2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $174.29 | 2021-2024 | Rexulti, Abilify Maintena |
| Janssen Scientific Affairs, LLC | $139.54 | 2023 | Invega Trinza, Spravato |
| Idorsia Pharmaceuticals US INC | $125.55 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $89.90 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $71.85 | 2021 | |
| Neos Therapeutics, Lp | $70.17 | 2021-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $69.38 | 2022-2023 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $68.50 | 2024 | Aristada, Lybalvi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $49.62 | 2023-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $47.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.80 | 2023-2024 | Austedo Xr, Uzedy |
| Noven Therapeutics, LLC | $44.39 | 2024-2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $36.70 | 2024 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $34.90 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.35 | 2025 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $15.29 | 2023 | Horizant |
| Almatica Pharma LLC | $14.82 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rise Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.